Arcus Biosciences Stock Forecast, Price & News

+0.95 (+2.64 %)
(As of 09/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume927,897 shs
Average Volume579,739 shs
Market Capitalization$2.64 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Arcus Biosciences logo

About Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.20 out of 5 stars

Medical Sector

341st out of 1,351 stocks

Pharmaceutical Preparations Industry

159th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

Is Arcus Biosciences a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Arcus Biosciences?

Wall Street analysts have given Arcus Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcus Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arcus Biosciences

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) released its earnings results on Wednesday, August, 4th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.87) by $0.22. The business had revenue of $9.46 million for the quarter, compared to the consensus estimate of $18.43 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 34.30% and a negative net margin of 213.68%.
View Arcus Biosciences' earnings history

How has Arcus Biosciences' stock been impacted by Coronavirus (COVID-19)?

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RCUS shares have increased by 118.0% and is now trading at $36.99.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RCUS?

8 Wall Street analysts have issued 12 month price targets for Arcus Biosciences' shares. Their forecasts range from $43.00 to $70.00. On average, they expect Arcus Biosciences' share price to reach $55.50 in the next twelve months. This suggests a possible upside of 50.0% from the stock's current price.
View analysts' price targets for Arcus Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:
  • Terry J. Rosen, Chairman & Chief Executive Officer
  • Juan Carlos Jaen, President & Director
  • Jennifer Jarrett, Chief Operating Officer & Director
  • Robert C. Goeltz, Chief Financial & Accounting Officer
  • Steve Young, Senior VP-Technology & Quantitative Biology

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.66%), FMR LLC (4.33%), BVF Inc. IL (3.92%), State Street Corp (3.76%), Vanguard Group Inc. (3.45%) and Woodline Partners LP (2.33%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences

Which institutional investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Balyasny Asset Management LLC, Goldman Sachs Group Inc., Invesco Ltd., Vanguard Group Inc., Citadel Advisors LLC, First Trust Advisors LP, and TimesSquare Capital Management LLC. Company insiders that have sold Arcus Biosciences company stock in the last year include Carolyn C Tang, Jennifer Jarrett, Juan C Jaen, Terry J Rosen, and William Grossman.
View insider buying and selling activity for Arcus Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Arcus Biosciences stock?

RCUS stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, FMR LLC, BlackRock Inc., State Street Corp, Woodline Partners LP, Octagon Capital Advisors LP, Nuveen Asset Management LLC, and Northern Trust Corp. Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Kathryn E Falberg, Robert C Goeltz II, William Grossman, and Yasunori Kaneko.
View insider buying and selling activity for Arcus Biosciences
or or view top insider-buying stocks.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $36.99.

How much money does Arcus Biosciences make?

Arcus Biosciences has a market capitalization of $2.64 billion and generates $77.52 million in revenue each year. The company earns $-122,860,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 236 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

Where are Arcus Biosciences' headquarters?

Arcus Biosciences is headquartered at 3928 Point Eden Way, Hayward CA, 94545.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at (510) 694-6200 or via email at [email protected].

This page was last updated on 9/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.